Open AccessPreclinical safety of human embryonic stem cell-derived oligodendrocyte progenitors supporting clinical trials in spinal cord injury
Author(s) -
Catherine A. Priest,
Nathan C. Manley,
Jerrod Denham,
Eric Wirth,
Jane Lebkowski
Publication year - 2015
Publication title -
regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 63
eISSN - 1746-076X
pISSN - 1746-0751
DOI - 10.2217/rme.15.57
Subject(s) - progenitor cell , medicine , oligodendrocyte , stem cell , spinal cord injury , embryonic stem cell , population , spinal cord , pharmacology , pathology , biology , central nervous system , myelin , microbiology and biotechnology , biochemistry , environmental health , psychiatry , gene
To characterize the preclinical safety profile of a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy product (AST-OPC1) in support of its use as a treatment for spinal cord injury (SCI).